Clinical trialNCT00377390CompletedObservational

ICATA Asthma Mechanistic Study

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment224Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. A subset of inner-city children and adolescents currently enrolled in Inner-City Anti-IgE Therapy for Asthma (a clinical trial of omalizumab) will be enrolled in this study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Carolyn Kercsmar, MD
Rainbow Babies and Children's Hospital
Principal Investigator
clinicaltrials.gov ↗
Hugh Sampson, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
clinicaltrials.gov ↗
Jacqueline Pongracic, MD
Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator
clinicaltrials.gov ↗
Rebecca S. Gruchalla, MD, PhD
University of Texas Southwestern Medical Center
Principal Investigator
clinicaltrials.gov ↗
William W. Busse, MD
University of Wisconsin, Madison
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Memorial Hospital
Chicago, Illinois, United States
Mount Sinai School of Medicine
New York, New York, United States
Rainbow Babies and Children'S Hospital
Cleveland, Ohio, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omalizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2006
Primary completion: 31 Dec 2009
Completion: 31 Dec 2009
Last update posted: 7 Feb 2013
Registered enrollment: 224
Registry id: NCT00377390

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.